Trial Profile
Phase II Study of Venetoclax (ABT-199/GDC-0199) in Combination With Obinutuzumab and Bendamustine in Patients With High Tumor Burden Follicular Lymphoma as Front Line Therapy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 11 Jan 2024
Price :
$35
*
At a glance
- Drugs Bendamustine (Primary) ; Obinutuzumab (Primary) ; Venetoclax (Primary)
- Indications B-cell lymphoma; Follicular lymphoma; Non-Hodgkin's lymphoma
- Focus Therapeutic Use
- Acronyms PrE0403
- 28 Feb 2023 Status changed from active, no longer recruiting to completed.
- 22 Dec 2021 Planned End Date changed from 1 Jan 2024 to 1 Jun 2023.
- 14 Dec 2021 Results assessing end of induction (EOI) outcomes presented at the 63rd American Society of Hematology Annual Meeting and Exposition